March 3–6 | Coronado, Calif.

2020 Deuel Conference on Lipids

Fat in Liver and Beyond

The Deuel conference takes place annually at a West Coast location for five sessions over two and a half days. The conference centers around an aspect of lipid metabolism and maintains an informal atmosphere, encourages free and open discussion, and is a forum for the presentation of new and unpublished data.

Attendees enjoy the informality and the meeting provides the depth and breadth of expertise necessary for a high quality conference. Participants are investigators in the field of lipids and lipoproteins from the around the world. Interested scientists are invited to attend and encourage trainees to submit abstracts.

Program Schedule

Tuesday March 3
Wednesday March 4
Thursday March 5
Friday March 6

Tuesday agenda

7:30 PM - 9:00 PM

The Havel Lecture

Dynamics of membrane trafficking, sorting and compartmentalization within eukaryotic cells
Jennifer Lippincott-Schwartz, HHMI Janelia Research Campus

Wednesday agenda

8:45 AM - 11:45 AM

Session 1: Genetics of NAFLD

Session Chair:  Jay Horton, University of Texas, Southwestern

Fatty Liver disease: a tale of two genes
Helen Hobbs, University of Texas Southwestern Medical Center
Use of GWAS to identify genes causing NASH
Elizabeth Speliotes, University of Michigan
New pathways for cellular and systemic lipid transport
Peter Tontonoz, University California, Los Angeles
Regulation of the degradation of SREBP2
Arun Radhakrishnan, University of Texas, Southwestern
Hepatic deletion of MBOAT7 (LPIAT1) causes activation of SREBP-1c and fatty liver
Matthew Mitsche, University of Texas, Southwestern
DYRK1B triggers de-novo lipogenesis by activating mTORC2 complex and is an attractive target for the treatment of non-alcoholic fatty liver disease
Arya Mani, Yale University
7:30 PM - 9:30 PM

Session 2: Role of lipids in NASH

Session Chair: Alan Tall, Columbia University

Journal of Lipid Research Award Lecture
Hepatocyte cholesterol signaling in TAZ-induced NASH fibrosis
Ira Tabas, Columbia University
Lipid droplets and non-alcoholic fatty liver disease
Robert Farese, Harvard School of Public Health
Journal of Clinical Investigation Award Lecture
Leveraging large-scale genomics and EHR-linked biobanks to understand NAFLD/NASH risk and identify novel therapeutic targets
Noura Abul-Husn, Mount Sinai School of Medicine
Loss of function of an atypical AAA+ ATPase, torsinA, results in severe NAFLD on a chow diet with marked reductions in VLDL secretion and accumulation of lipid droplets within the nucleus and ER
Henry Ginsberg, Columbia University
Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis
Xiaoli Sun, University of California, San Diego

Thursday agenda

8:45 AM - 11:45 AM

Session 3: Fatty liver, TRLs and atherosclerosis

Session Chair: Rebecca Haeusler, Columbia University

DGAT2 inhibition for the treatment of NASH
Morris Birnbaum, Pfizer Inc.
A new era for treatment of hypertriglyceridemia; or not?
Henry Ginsberg, Columbia University
Role of de novo lipogenesis in NAFLD
Sam Klein, Washington University in St. Louis
The multifaceted roles of adipose tissue for diabetes and fatty liver
Philipp Scherer, UT Southwestern
Role of liver-derived angiopoietin-like protein 4 in metabolic diseases
Abhishek Singh, Yale University
Identifying tissue-specific actions of angiopoietin-like 4 during high fat diet feeding in mice
Kathryn Spitler, University of Iowa
7:30 PM - 9:30 PM

Session 4: Fat to NASH and beyond

Session Chair: Ira Tabas, Columbia University

NASH, fibrosis and HCC – Diagnostic and therapeutic frontiers
Scott Friedman, Mount Sinai School of Medicine
Notch activation induces NASH-associated fibrosis
Utpal Pajvani, Columbia University
Innate immune signaling in NASH/ASH
Wajahat Mehal, Yale University
Deletion of hepatic Ppp1r3b causes dysregulated glucose and lipid metabolism that precedes steatosis in mice
Kate Townsend Creasy, University of Pennsylvania
TMEM55B regulates hepatic fatty acid oxidation
Yuanyuan Qin, University of California, San Francisco

Friday agenda

9:00 AM - 10:30 PM

Session 5: Emerging therapies for NASH

Session Chair: Joseph Witztum, University of California, San Diego

Combination therapies for NASH
Chinweike Ukomadu, Novartis Institutes for Biomedical Research
Characterization of FGF19 analogues for NASH
Lei Ling, NGM Biopharmaceuticals
ACC inhibition for the treatment of NASH
Chuhan Chung, Gilead Sciences, Inc.


Additional resources


Opportunities for companies that have a general interest in the areas of lipid metabolism, atherosclerosis, obesity, diabetes and Alzheimer's disease.

The Havel Lecture

About Richard J. Havel and past lecturers.

Past meetings

View the programs of past Deuel conferences.

Deuel Board

The Deuel conference board is responsible for organizing the meeting.


Bylaws of the ASBMB Deuel Conference on Lipids.